American Journal of Clinical Pathology · 2023 · 62 citations · 17 references
MedicineOncologyPathologyBreast OncologyMolecular OncologyTumor ImmunologyBiomarker ValidationBreast Cancer OncologyBreast PathologyHer2-positive Breast CancerImmuno-oncology BiomarkersImmunohistochemistryBreast Cancer Molecular SubtypesHer2 ExpressionHer2 Gene AmplificationInterobserver Reliability AssessmentInterobserver ReproducibilityMonoclonal Antibody AssaysReproducibility AnalysisReproducibility Assessment
OBJECTIVES: We assessed the interobserver and interantibody reproducibility of HER2 immunohistochemical scoring in an enriched HER2-low-expressing breast cancer cohort. METHODS: A total of 114 breast cancer specimens were stained by HercepTest (Agilent Dako) and PATHWAY anti-HER2 (4B5) (Ventana) antibody assays and scored by 6 breast pathologists independently using current HER2 guidelines. Level of agreement was evaluated by Cohen κ analysis. RESULTS: Although the interobserver agreement rate for both antibodies achieved substantial agreement, the average rate of agreement for HercepTest was significantly higher than that for the 4B5 clone (74.3% vs 65.1%; P = .002). The overall interantibody agreement rate between the 2 antibodies was 57.8%. Complete interobserver concordance was achieved in 44.7% of cases by HercepTest and 45.6% of cases by 4B5. Absolute agreement rates increased from HER2 0-1+ cases (78.1% by HercepTest and 72.2% by 4B5; moderate agreement) to 2-3+ cases (91.9% by HercepTest and 86.3% by 4B5; almost perfect agreement). CONCLUSIONS: Our results demonstrated notable interobserver and interantibody variation on evaluating HER2 immunohistochemistry, especially in cases with scores of 0-1+, although the performance was much more improved among breast-specialized pathologists with the awareness of HER2-low concept. More accurate and reproducible methods are needed for selecting patients who may benefit from the newly approved HER2-targeting agent on HER2-low breast cancers.
17
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita et al. · New England Journal of Medicine · 2022 · 2.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text
Udai Banerji, Carla M.L. van Herpen, Cristina Saura et al. · The Lancet Oncology · 2019 · 565 citations · Full text
Medicine, Oncology, Pharmacology +17